
    
      First line therapy: open labeled, randomized control trial, randomized into one of the three
      groups Group (A): triple therapy for 14 days D1-D14: (lansoprazole 30mg + clarithromycin
      500mg + amoxicillin 1gm) bid Group (B): non-bismuth quadruple therapy for 10 days D1-D10:
      lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg
      bid Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid +
      colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid

      Second line therapy: patients who fail from first line treatment will be rescue with the
      following treatment Group (A) Patient who fail from triple therapy will be retreated with
      bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth
      subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid Group (B) Patient who
      fail from non-bismuth quadruple therapy will be retreated with bismuth quadruple therapy for
      10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid +
      metronidazole 500mg tid + tetracycline 500mg tid Group (C) Patients who fail from bismuth
      quadruple therapy will be retreated with non-bismuth quadruple therapy for 10 days D1-D10:
      lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg
      bid
    
  